Persistence of neutralizing antibodies after discontunuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 247-252

  Petersen, Bodil ^a   Bendtzen, Klaus ^b   Koch Henriksen, Nils ^a,c   Ravnborg, Mads ^a   Ross, Christian ^b   Sorensen, Per Soelberg ^a   frederiksen, Jette Lautrup ^d   Jensen, Kai ^e   Heltberg, Anne ^f   Schaldemose, Hanne ^g   Boesen, Finn ^h   Deth, Sven ⁱ   Kristensen, Ole ^j   Worm, Mogens ^k   Stenager, Egon ^l  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e HILLERØD HOSPITAL   (Denmark)

^f ROSKILDE HOSPITAL   (Denmark)

^g HOLBÆK HOSPITAL   (Denmark)

^h SLAGELSE HOSPITAL   (Denmark)

ⁱ Vejle and Esbjerg Hospital   (Denmark)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k VIBORG HOSPITAL   (Denmark)

^l HOLSTEBRO HOSPITAL   (Denmark)

more..

Author keywords

IFN therapy; IFN 1a; IFN 1b; Neutralizing antibodies; Relapsing remilling multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DENMARK; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTRALIZATION TESTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33744781321     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248505ms1324oa     Document Type: Article

References (28)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
2. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
5. SPECTRIMS. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
6. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-17.
7. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95.
8. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496-506.
9. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
10. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
11. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
12. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
13. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73: 148-53.
14. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group [In Process Citation]. Ann Neurol 2000; 48: 706-12.
15. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-79.
16. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 1998; 18: 345-50.
17. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Richert JR et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999; 2: 1-6.
18. Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 2004; 109: 66-70.
19. Koch-Henriksen N, Sorensen PS. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000; 6: 172-75.
20. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61: S6-S10.
21. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
22. Ross C, Svenson M, Clemmesen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon-beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39-46.
23. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-55.
24. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21: 729-42.
25. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J et al. Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis-Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 1-11.
26. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
27. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-56.
28. Perini P, Facchinetti A, Bulian P, Massaro AR, De Pascalis D, Bertolotto A et al. Interferon-beta (IFN-beta) antibodies in interferon-beta 1a- and interferon-beta 1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61.